Labcyte and Stanford University Collaborate on Advanced Biomarker Validation Program
Labcyte announced the award of $196K from the National Cancer Institute to fund a collaborative cancer biomarker validation program with the Canary Center of Stanford University. The program will develop an advanced system for early cancer detection by integrating a suite of well-established biotechnologies that includes Labcyte proprietary acoustic liquid handling for arraying and MALDI mass spectrometry preparation.
Biomarkers are a key focus of diagnostic development with research in this field leading to the discovery of thousands of protein indicators of disease states. More recently, the challenge for diagnostic development has become one of validation-deciding which biomarkers correlate most closely with their respective diseases and are therefore best suited for more intensive development.